FDA Orders Rare Vision-Loss Warning for GLP-1 Drugs
The FDA ordered manufacturers of GLP-1 medicines, including Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound, to add warnings about possible NAION, a rare optic-nerve condition that can cause permanent vision loss. The agency's review found roughly 6 NAION cases per 100,000 patients taking a GLP-1 for at least one year, compared with less than 4 per 100,000 for placebo or other glucose-lowering medicines. Novo Nordisk said the data do not establish causation and that it remains confident in its medicines' benefit-risk profile, while Eli Lilly said it was evaluating the update.
Why it matters
The label change adds a safety disclosure across the GLP-1 class and may increase monitoring, legal scrutiny and concern among patients using the medicines. Citi analysts cited in material 20 expect limited effects on GLP-1 adoption because NAION is rare and the drugs' benefits remain substantial.
Key facts
- 1The FDA requires all GLP-1 drug labels to warn about possible NAION, including labels for Ozempic, Wegovy, Mounjaro and Zepbound. cbsnews.com
- 2An FDA analysis of more than 125 clinical trials found roughly 6 NAION cases per 100,000 patients taking a GLP-1 for at least one year, versus less than 4 per 100,000 among placebo or other glucose-lowering treatment groups. cbsnews.com
- 3A review of 126 clinical trials involving 134,253 participants identified 10 probable NAION cases among GLP-1 users and five among placebo recipients. ynetnews.com
- 4After adjusting for treatment exposure, the review calculated 6.4 NAION cases per 100,000 patient-years for GLP-1 medicines and 3.8 cases in comparison groups. ynetnews.com
- 5Novo Nordisk said the available data do not establish a cause-and-effect relationship and that it remains confident in the benefit-risk profile of its GLP-1 medicines. cbsnews.com
Summary written by AlphAI AI Desk from 20 of 20 sources. Not investment advice. Figures are as stated by the linked sources.